Skip to main content

Advertisement

SpringerLink
Log in

Aus internistischer Sicht

From the internal medical point of view

  • Published:
Acta Chirurgica Austriaca Aims and scope Submit manuscript

Zusammenfassung

Der Wert einer adjuvanten Chemotherapie des Kolonkarzinoms wurde in zahlreichen randomisierten Studien geprüft. Während frühere Untersuchungen keinen gesicherten Vorteil für die behandelten Patienten ergaben, zeigten zwei größere neue Studien einen Vorteil für Patienten, die mit 5-Fluorouracil und Levamisol behandelt wurden. Ein Überlebensvorteil ergab sich vor allem für Patienten mit positivem Lymphknoten (=Dukes C). Weitere Untersuchungen sind jedoch erforderlich, um die Ergebnisse weiter abzusichern, auch gibt es noch eine Reihe von ungelösten Fragen, wie zum Beispiel die Dauer der Behandlung.

Summary

Numerous randomized trial have been performed to analyse the value of adjuvant chemotherapy in colon carcinoma. Previous studies failed to show a benefit for the treatment group, compared with controls. Two recent trials revealed a benefit for patients treated with 5-fluorouracil and levamisol. An improved survival was seen in patients with positive lymph nodes (=Dukes C). Further studies are required to confirm these results. Additionally, there exists a number of unresolved quesions, e.g. the optimal duration of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Buyse M, Zelenuich-Jaquotte A, Chalmers TC: Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;259:3571–3578.

    Article  PubMed  CAS  Google Scholar 

  2. Einhorn LH: Improvements in fluorouracil chemotherapy. J Clin Oncol 1989;7:1377–1379.

    PubMed  CAS  Google Scholar 

  3. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447–1456.

    PubMed  CAS  Google Scholar 

  4. Mayer RJ, O'Connell MJ, Tepper JE, Wolmark N: Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 1989;81;1359–1364.

    Article  PubMed  CAS  Google Scholar 

  5. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–358.

    Article  PubMed  CAS  Google Scholar 

  6. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmermann M, Itri L, Weinberg V, Wiernik P: Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769–1775.

    PubMed  CAS  Google Scholar 

  7. Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Onkologie, Department Innere Medizin, Kantonsspital Basel, Petersgraben 4, CH-4031, Basel, Schweiz

    H. Denz, C. Ludwig & R. Herrmann

Authors
  1. H. Denz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denz, H., Ludwig, C. & Herrmann, R. Aus internistischer Sicht. Acta Chir Austriaca 23, 244–245 (1991). https://doi.org/10.1007/BF02663236

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02663236

Schlüsselwörter

Key-words

Search

Navigation